Si Meijun, Li Huiqun, Chen Yanru, Peng Hui
Nephrology Division, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
BMJ Case Rep. 2018 May 18;2018:bcr-2017-223187. doi: 10.1136/bcr-2017-223187.
Ethambutol (EMB) and isoniazid (INH) are the first-line antituberculosis (anti-TB) drugs. However, their neurotoxicity could cause adverse effect and the patients with end-stage renal disease are especially vulnerable due to the reduction in renal drug clearance. Here, we report a 36-year-old man receiving peritoneal dialysis developed progressive paralysis in lower extremities, vision loss and hoarseness 4 months after anti-TB treatment with INH, EMB and rifapentine because of concomitant pulmonary tuberculosis. A diagnosis of EMB/INH-induced peripheral neuropathy, retrobulbar neuritis and laryngoparalysis was made. The patient's neuropathy gradually improved 2 years after discontinuation of EMB/INH. Since EMB and INH may cause simultaneously severe and complex multineuropathy in dialysis patients, their adverse effects should be closely supervised in dialysis patients.
乙胺丁醇(EMB)和异烟肼(INH)是一线抗结核药物。然而,它们的神经毒性可能会引起不良反应,而终末期肾病患者由于肾脏药物清除率降低,尤其易受影响。在此,我们报告一名36岁接受腹膜透析的男性,因合并肺结核接受INH、EMB和利福喷丁抗结核治疗4个月后出现双下肢进行性麻痹、视力丧失和声音嘶哑。诊断为EMB/INH诱发的周围神经病、球后视神经炎和喉麻痹。停用EMB/INH 2年后,患者的神经病变逐渐改善。由于EMB和INH可能同时在透析患者中引起严重且复杂的多神经病,因此在透析患者中应密切监测它们的不良反应。